"None of these headwinds can be faced without us bending. From my perspective, this move is a response to those changes, and it demonstrates our ability to be able to meet a challenge - it is important because it is going to continue," he told BioPharmaDispatch.
Dennis Bastas on Arrotex and creating the largest company by volume in PBS history
July 11, 2019 Latest NewsBioPharmaDispatch ExecutiveNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Podcast - Week in review
August 7, 2026 - - Podcast -
argenx partners with Monash University and Myostellar to develop muscular therapies
August 7, 2026 - - Latest News -
A new generation is rewriting their lives living with Cystic Fibrosis
August 7, 2026 - - Latest News -
US approves Moderna's mRNA flu vaccine in major technology milestone
August 7, 2026 - - Latest News -
If Australian companies shun their domestic market, who can blame multinationals?
August 6, 2026 - - Latest News -
Neuren reports record DAYBUE sales as royalties rise and global expansion nears
August 6, 2026 - - Australian Biotech -
Moderna begins Phase 1 trial of vaccine candidate against Bundibugyo Ebola Virus
August 6, 2026 - - Latest News

